Skip to main content
Equibles
NRXS logo

NRXS

Neuraxis, INC
$7.13 -0.03 (-0.42%) At close · Jul 7
Market Cap
$88.30M
Shares
12,384,405

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.13 Open$7.20 Day$7.10–7.46 52W$2.20–9.33 Avg vol 30d104K Short int508K · 4.1% float · 3.7d Short vol38% Last earningsMay 12, 2026 DataAug 2023–Jul 2026 Filing10-Q · May 12
Equibles Rating blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +38%
above
Price vs 50-day avg −4%
below
RSI (14) 50
neutral
MACD trend Positive
52-week position 69%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +4%
trailing
6-month return +38%
trailing
YTD return +57%
this year
Relative strength +31%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+44% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.10% of float · ▼ -2.5% MoM · 3.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
26 holders — near 3-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Excellent
Revenue growth +33%
Y/Y
Gross margin 84%
contracting
EPS growth +22%
Y/Y
Free cash flow $-6.5M
Balance sheet $4.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −40%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Sep 28, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 12, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Buy
      0 · 5 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +38% Bullish
      Price vs 50-day avg
      −4% Neutral
      RSI (14)
      50 Neutral
      MACD trend
      Positive Bullish
      52-week position
      69% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $7 › 200d $5 — 50d above 200d
      Institutional flow Accumulating
      +44% holders QoQ · +12 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.10% of float · ▼ -2.5% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      26 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $2 Now $7 · 69% 52-wk high $9
      vs 200-day avg +38% vs 50-day avg -4%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      IB-Stim average selling price (ASP) $1,020 Q1 2026 call —
      Internal prior authorization approval percentage 32% Q1 2026 call —
      Number of ordering accounts 66 Q1 2026 call —
      Total covered lives 101M Q1 2026 call —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NRXS
      Neuraxis, INC
      this stock
      		$88.30M +57.0% +32.9% — 4.1%
      ONC
      BeOne Medicines Ltd.
      		 $446.53B +1.7% +22179.2% 908.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $132.55B +15.2% +46.2% 31.0 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $70.90B -12.3% +20.8% 16.5 3.2%
      ARGX
      Argenx SE
      		 $57.20B +8.8% — — 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      26
      % held
      16.5%
      Net QoQ
      +467.5K sh
      Top holder
      BIGGER CAPITAL FUND L P
      Held Float
      View
      Held by Funds
      Fund positions
      7
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      507.5K
      Days to cover
      3.7d
      Change
      -13.0K sh
      View
      Short Volume
      Short vol %
      38%
      As of
      Jul 8, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      7.5K
      Value
      $51.5K
      As of
      Jun 8, 2026
      View
      Off-Exchange
      Off-exchange %
      55.5%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $3.6M
      Net income (FY)
      $-7.8M
      EPS diluted
      $-0.95
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 12, 2026
      This year
      6
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NRXS -0.1% +4.2% +38.5% -2.5% +57.1%
      SPY +0.9% +1.4% +7.6% +0.1% +9.7%
      vs SPY -1.1% +2.9% +30.9% -2.6% +47.4%
      Key facts CIK 1933567 CUSIP 64134X201 Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)